Clinical Trial Update: Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia [Phase 2]

View source ↗

Summary

The update notes the completion of a Phase 2 trial evaluating subcutaneous darbepoetin alfa in patients with symptomatic congestive heart failure and anemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Heart Failure

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)

Snippet

Sponsor: Amgen | Conditions: Congestive Heart Failure, Anemia | Phase 2 | Status: COMPLETED